Scancell Holdings (SCLP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

10.25p
   
  • Change Today:
      0.25p
  • 52 Week High: 19.50
  • 52 Week Low: 7.50
  • Currency: UK Pounds
  • Shares Issued: 1,036.78m
  • Volume: 409,598
  • Market Cap: £106.27m

Company Description

Scancell is a biopharmaceutical company focused on the cancer therapeutics market.

IPO Details

Issue Date 30-Jul-2010 Prospectus n/a
Issue Price n/a Lead Broker Zeus Capital
Market Cap £9.95m Contact Tel 0161 831 1512
Method Introduction    
Sector Pharmaceutical & Biotechnology    
Market Aim    
Amount Raised £0.00m    

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

SCLP Market Data

Currency UK Pounds
Share Price 10.25p
Change Today 0.25p
% Change 2.50 %
52 Week High 19.50
52 Week Low 7.50
Volume 409,598
Shares Issued 1,036.78m
Market Cap £106.27m

SCLP Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
6.5% below the market average6.5% below the market average6.5% below the market average6.5% below the market average6.5% below the market average
Sector averageSector averageSector averageSector averageSector average
Price Trend
27.47% below the market average27.47% below the market average27.47% below the market average27.47% below the market average27.47% below the market average
21.74% above the sector average21.74% above the sector average21.74% above the sector average21.74% above the sector average21.74% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 3
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

SCLP Dividends

No dividends found

Trades for 11-Jul-2025

Time Volume / Share Price
16:26 3,849 @ 10.29p
16:13 4,179 @ 10.29p
16:05 24,203 @ 10.29p
15:46 41,837 @ 10.29p
15:05 100,000 @ 10.13p

SCLP Key Personnel

CFO Sath Nirmalananthan
CEO Phil L'Huillier

Top of Page